Abstract:ObjectiveTo construct a recombinant Listeria ivanovii (LI) strain that expressed Mycobacterium tuberculosis (MTB) specific antigen protein as a novel multistage tuberculosis (TB) vaccine candidate, and evaluate the biosafety and immunogenicity in mouse model.MethodsT cell epitopes of four genes related to different stages of MTB infection were fused in series to form an antigen gene, i.e. the multistage antigen gene (named msv). Then msv was inserted into the targeting plasmid that contained LI homologous sequences. Recombinant LI strain was obtained by transfecting LI with targeting plasmid and screening the recombinant LI strain that carried msv in the genome after series of homologous gene recombination processes. The growth rate of the recombinant LI strain in vitro was observed and the expression of target protein was verified by Western blot. The 50% lethal dose (LD 50) of the recombinant strain to C57BL/6 mice was measured. Mice were intravenously inoculated with vaccine candidate in dose of 0.1×LD 50.The serum alanine aminotransferase (ALT) levels, bacterial load in organs, and organ pathological sections before and 1, 2, 3, 5, 7, 14 d after vaccination were used to evaluate the safety of vaccine candidate strain. To analyze the immunogenicity of vaccine candidate strain, mice were intravenously inoculated with LI- msv, LI, and NS respectively. Nine days post immunization, the spleens were isolated under sterile conditions and splenocytes were collected and stimulated. Lyphocytes which secret specific cytokines, interferon (IFN)-γ, tumor necrosis factor (TNF)-α and interleukin (IL)-2 were analyzed by flow cytometry.ResultsA recombinant strain named LI- msv which was capable of expressing the multistage TB antigen protein was successfully constructed. The LD 50 value of LI- msv for C57BL/6 mice (i.v.) was 3.3×10 8 CFU. After intravenously immunized the mice, this strain mainly multiplied in the liver and spleen, and was cleared at 7 d post innoculation. Such infection process caused transient pathological damages of the liver and spleen. Results of flow cytometry showed specific IFN-γ + CD4 + and IFN-γ + CD8 +T lymphocytes were successfully induced in LI -msv immunized mice spleen lymphocytes. The frequency of IFN-γ positive CD4 + and CD8 +T cells was significantly higher than those of vector control group and NS control group ( P<0.005). Additionally, the frequency of specific TNF-α + CD4 + T cell in LI -msv immunized group was significantly higher than that of vector control ( P<0.01) and NS control group ( P<0.005), and TNF-α + CD8 + T cell frequency obviously increased than NS control group ( P<0.005).ConclusionsA novel multistage TB vaccine candidate expressing TB multistage antigen based on LI was successfully constructed. This vaccine candidate is safe and can induce specific cellular immune response to some extent. It is promising to be further studied as a candidate vaccine against tuberculosis.

Construction of BP26 tagged vaccine strain and development of discriminating PCR for Brucella]

Brucella Melitensis M5-90Δbp26 As a Potential Live Vaccine That Allows for the Distinction Between Natural Infection and Immunization.

[Construction and Evaluation of a Tuberculosis Multistage Vaccine Candidate Based on Recombinant Listeria Ivanovii].

Construction and Evaluation of the Brucella Double Gene Knock-out Vaccine Strain MB6 Δbp26ΔwboA (RM6)

The 16m Delta Vjbr As An Ideal Live Attenuated Vaccine Candidate For Differentiation Between Brucella Vaccination And Infection

The 16MΔvjbR as an ideal live attenuated vaccine candidate for differentiation between Brucella vaccination and infection.

The Brucella Melitensis M5-90ΔmanB Live Vaccine Candidate is Safer Than M5-90 and Confers Protection Against Wild-Type Challenge in BALB/c Mice.

Attenuation Mechanism of Brucella Melitensis M5-10, Implications for Vaccine Development and Differential Diagnosis

Expression, Purification, and Improved Antigenic Specificity of a Truncated Recombinant Bp26 Protein of Brucella Melitensis M5-90: a Potential Antigen for Differential Serodiagnosis of Brucellosis in Sheep and Goats.

A rapid minor groove binder PCR method for distinguishing the vaccine strain Brucella abortus 104M

[Construction of Brucella Abortus A19-delta VirB12 Mutant and Evaluation of Its Protective Efficacy Against 2308 Strain Challenge in BALB/c Mice].

Brucella melitensis 16MΔTcfSR as a potential live vaccine allows for the differentiation between natural and vaccinated infection.

A subunit vaccine based on <italic>Brucella melitensis</italic> rBP26 induces Th1 immune responses and M1 macrophage activation

Construction of the recombinant expression plasmid BCSP31/pVAX1 of Brucella and evaluation of its immuno-protective effect

Altered Transcriptome of the B. melitensis Vaccine Candidate 16MΔvjbR, Implications for Development of Genetically Marked Live Vaccine

Study on the Biological Characteristics of Vaccine Candidate RB6 Derived from Brucella abortus

Construction and Identification of Mutation of Pgm Gene Attenuate the Virulent of Brucella Melitensis Strain 16

A Potent Brucella Abortus 2308 Δery Live Vaccine Allows for the Differentiation Between Natural and Vaccinated Infection

Altered Transcriptome Of The B-Melitensis Vaccine Candidate 16m Delta Vjbr, Implications For Development Of Genetically Marked Live Vaccine

Mutant strain of Brucella bacterin with weak poison, constructing method, and application

Characterization of Brucella Abortus Mutant Strain Δ22915, a Potential Vaccine Candidate